Salentra Biosciences

Executive Summary

Salentra Biosciences is a private biotechnology startup based in St. Louis, Missouri, founded in 2018. The company specializes in differentiating human stem cell-derived islets (SCIslets) to generate functionally mature pancreatic islets at scale. Its proprietary technology aims to produce high-quality SCIslets for commercial distribution as research tools, targeting the acceleration of diabetes research. By leveraging strong academic partnerships, Salentra seeks to address the critical need for reliable and scalable in vitro models in diabetes drug discovery and basic science. While the company has not disclosed fundraising details or clinical stage, its focus on the research tool market offers a lower-risk entry point compared to therapeutic development, potentially enabling early revenue generation. With a dedicated team and a unique differentiation platform, Salentra is positioned to support the growing demand for physiologically relevant human islet models, which are currently limited in supply and functionality.

Upcoming Catalysts (preview)

• Q4 2026First commercial release of SCIslets for research use60% success
• Q3 2026Strategic partnership with academic diabetes center50% success
• Q1 2027Series A funding round40% success